Kara D. Dobbin

FDA investigator · also recorded as Bi Kara D. Dobbin

Appears on 5 documents from 2017 to 2020, most often at sites in China. Most often cites batch production and control records (21 CFR 211.188).

5
Documents on file
3.8
Observations per 483
2017
First seen
2020
Most recent

What they cite most

From 19 observations

Activity by year

2017: 1, 2018: 1, 2019: 2, 2020: 1

Where

China 1 · Georgia 1 · India 1 · Mexico 1 · North Carolina 1

Often inspects with

Reba A. Gates· Daveta L. Bailey

Is Kara D. Dobbin coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

5 documents, newest first
FirmOpen
483 Lifequest Creations LLCMar 9, 2020 · Marietta, Georgia
483 AGON PHARMA PRIVATE LIMITEDJun 13, 2019 · Pune, India
483 Zhejiang Dingtai Pharmaceutical Co., LtdJan 25, 2019 · Tongxiang, China
483 Form 483 · FEI 3003722350Jul 22, 2018 · San Nicolas de los Garza, Mexico
483 The Procter & Gamble Manufacturing CompanyMar 10, 2017 · Browns Summit, North Carolina

About this profile

What does Kara D. Dobbin inspect?

Kara D. Dobbin appears on 5 documents on file covering 5 sites, most often in China.

What do they cite most often?

21 CFR 211.188 (batch production and control records), followed by 21 CFR 211.100(a) and 21 CFR 211.105(a).

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Kara D. Dobbin is dated Mar 9, 2020.

FDA Investigator Kara D. Dobbin: 483s & Inspections · FDA Intel